Vaccines Market

Vaccines Market (Vaccine: Inactivated, Live Attenuated, Toxoid, Conjugate, and Others; and Valance: Monovalent and Multivalent) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Vaccines Market Outlook 2031

  • The global industry was valued at US$ 119.1 Bn in 2022
  • It is estimated to grow at a CAGR of 4.2% from 2023 to 2031 and reach US$ 99.3 Bn by the end of 2031

Analyst Viewpoint

Rise in prevalence of infectious diseases is one of the key factors driving the demand for various types of vaccines across the globe. Increase in vaccination and immunization programs conducted by public healthcare organizations and governments is also fueling market progress. Furthermore, surge in advancements in immunology is augmenting the vaccines industry growth.

Children and the elderly population are more prone to infectious diseases. Thus, vaccination and immunization plays a crucial role in their well-being. Manufacturers are increasingly carrying out advancements such as genetic engineering and lab automation to strengthen their vaccines market share. They are also investing significantly in research and development activities to introduce new vaccines for major infectious diseases.

Global Vaccines Market

Market Introduction

Vaccine is a biological preparation that provides active acquired immunity to a particular malignant or infectious disease. It contains an agent that resembles a disease-causing microorganism and is made from killed or weakened forms of the microbe, its toxins, or one of its surface proteins.

Vaccination is a safe, effective, and simple way of providing protection against harmful diseases. It uses the body’s natural defenses to build resistance to specific infections and makes the immune system stronger.

There are several types of vaccines such as live-attenuated vaccines, inactivated vaccines, messenger RNA (mRNA) vaccines, toxoid vaccines, viral vector vaccines, subunit, recombinant, polysaccharide, and conjugate vaccines.

Vaccines contain synthetically manufactured, weakened, or killed versions of the disease-causing germ or parts of the germ called antigens.

Rise in Prevalence of Infectious Diseases Driving Vaccines Market Growth

Infectious diseases such as tuberculosis, dengue, influenza, HIV, and malaria require proper cure at their initial stage to avoid severe health consequences. Rise in prevalence of these diseases among the global population is bolstering market development.

Manufacturers of vaccines are focusing on expanding their production capacity to meet the increasing consumer demand. According to the European Centre for Disease Prevention and Control, approximately 4.5 million dengue cases were reported globally, while 4000 deaths were confirmed until the beginning of November 2023.

Increase in prevalence of infectious diseases among children is fueling the demand for preventive vaccines. Rise in awareness among people about the benefits of vaccination is expected to drive market trajectory in the next few years.

As per a report by the World Health Organization 2023, the number of zero-dose children improved from 18.1 million in 2021 to 14.3 million in 2022. Also, 84% of the children were vaccinated with a third dose of vaccine protecting against Diphtheria, Tetanus, and Pertussis (DTP3).

Increase in Focus on Therapeutic Vaccines Propelling Vaccines Market Value

Therapeutic vaccines are used to treat various illnesses such as infectious diseases, allergies, physical disorders, and cancer. Increase in advancements in immunology is anticipated to boost the vaccines market size in the next few years.

Companies in the vaccines sector are focusing on therapeutic vaccine development for diseases such as dyslipidemia, inflammatory diseases, cancer, Alzheimer’s disease, and hypertension. For instance, in January 2022, Pfizer Inc. and BioNTech SE commenced a clinical evaluation to identify tolerability, safety, and immunogenicity of the Omicron-based vaccine in adults.

Growth in investment in research and development activities is also likely to augment the availability of vaccines across the globe. Healthcare organizations are carrying out mass vaccination programs to increase the vaccination rate across the globe.

Lab automation and adoption of mRNA vaccines are some of the key vaccines industry trends adopted by the leading companies. mRNA vaccines can be developed at a faster rate using the pathogen’s genetic code. Such advancements are expected to fuel market dynamics.

Regional Outlook

As per the latest vaccines market forecast, North America accounted for dominant share in 2022. Rapid development in the healthcare sector in the U.S. is augmenting market statistics in the region.

Ongoing medical research activities by manufacturers are leading to an increase in product development rate in North America. Rise in investment from government and non-government organizations in research and development of vaccines is another key factor that is likely to boost the region’s vaccines industry size in the upcoming years.

Asia Pacific is anticipated to record significant market expansion in the near future due to the growth in patient population. Increase in government spending on immunization programs such as the Universal Immunization Program is fueling the sector in the region. The Universal Immunization Program aims to prevent diseases such as smallpox, polio, and measles.

Analysis of Key Players

According to the vaccines market research report, key players are adopting various strategies such as partnership agreements and new product launches to expand their footprint and maintain their leading position.

AstraZeneca, GlaxoSmithKline PLC, Sanofi Pasteur SA, Pfizer, Inc., Panacea Biotec, Merck & Co., Inc., Janssen Pharmaceutical Company, Serum Institute of India Ltd, Emergent BioSolutions Inc., CSL, Bavarian Nordic, IBSS BIOMED S.A., Novavax AB, and Mitsubishi Tanabe Pharma Corporation are some of the prominent players operating in the global landscape.

Each of these companies has been profiled in the vaccines industry forecast report based on parameters such as business strategies, company overview, business segments, financial overview, recent developments, and product portfolio

Key Developments

  • On October 20, 2023, Pfizer Inc. received the U.S. Food and Drug Administration approval for PENBRAYA. It is the first and only vaccine to prevent the most common serogroups causing meningococcal disease in adolescents and young adults aged 10-25 years.
  • On October 31, 2023, GSK plc and Arrowhead Pharmaceuticals Inc. announced an agreement with Janssen Pharmaceuticals, Inc. to transfer exclusive rights to further develop and commercialize JNJ-3989 to GSK. JNJ-3989 was initially in-licensed by Janssen from Arrowhead in 2018.

Vaccines Market Snapshot

Attribute Detail
Market Size in 2022 US$ 119.1 Bn
Market Forecast (Value) in 2031 US$ 99.3 Bn
Growth Rate (CAGR) 4.2%
Forecast Period 2023-2031
Historical Data Available for 2017-2022
Quantitative Tons US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy and recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Vaccine
    • Inactivated
    • Live Attenuated
    • Toxoid
    • Conjugate
    • Others
  • Valance
    • Monovalent
    • Multivalent
  • Route of Administration
    • Oral
    • Injectable
      • Intramuscular
      • Subcutaneous
    • Others
  • Indication
    • Influenza
    • Hepatitis
    • Polio
    • Meningococcal Disease
    • Pneumococcal Disease
    • DTP
    • Rotavirus
    • MMR
    • Human Papilloma Virus
    • Others
  • Distribution Channel
    • Institutional Sales
    • Hospital Pharmacies
    • Retail Pharmacies
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Brazil
  • Mexico
  • South Africa
  • GCC countries
Companies Profiled
  • AstraZeneca
  • GlaxoSmithKline PLC
  • Sanofi Pasteur SA
  • Pfizer, Inc.
  • Panacea Biotec
  • Merck & Co., Inc.
  • Janssen Pharmaceutical Company
  • Serum Institute of India Ltd
  • Emergent BioSolutions Inc.
  • CSL
  • Bavarian Nordic
  • IBSS BIOMED S.A.
  • Novavax AB
  • Mitsubishi Tanabe Pharma Corporation
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global vaccines market in 2022?

It was valued at US$ 119.1 Bn in 2022

How is the vaccines business expected to grow by 2031?

It is anticipated to grow at a CAGR of 4.2% from 2023 to 2031

What are the key factors driving the demand for vaccines?

Rise in prevalence of infectious diseases and increase in advancements in immunology

Which region was the most lucrative for vaccines in 2022?

North America was the most lucrative region in 2022

Who are the prominent vaccine manufacturers?

AstraZeneca, GlaxoSmithKline PLC, Sanofi Pasteur SA, Pfizer, Inc., Panacea Biotec, Merck & Co., Inc., Janssen Pharmaceutical Company, Serum Institute of India Ltd, Emergent BioSolutions Inc., CSL, Bavarian Nordic, IBSS BIOMED S.A., Novavax AB, and Mitsubishi Tanabe Pharma Corporation

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Vaccines Market

    4. Market Overview

        4.1. Introduction

        4.2. Definition

        4.3. Industry Evolution / Developments

        4.4. Overview

        4.5. Market Dynamics

            4.5.1. Drivers

            4.5.2. Restraints

            4.5.3. Opportunities

        4.6. Global Vaccines Market Analysis and Forecast, 2017-2031

            4.6.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Regulatory Scenario

        5.2. Key Distribution Strategies

        5.3. Pricing Analysis

        5.4. Patents on Vaccines

        5.5. Technological Advancements in Vaccines

        5.6. Vaccine Type - Overview

        5.7. COVID-19 Pandemic Impact on Industry

    6. Global Vaccines Market Analysis and Forecast, by Vaccine

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Vaccine, 2017-2031

            6.3.1. Inactivated

            6.3.2. Live Attenuated

            6.3.3. Toxoid

            6.3.4. Conjugate

            6.3.5. Others

        6.4. Market Attractiveness Analysis, by Vaccine

    7. Global Vaccines Market Analysis and Forecast, by Valance

        7.1. Introduction & Definition

        7.2. Developments

        7.3. Market Value Forecast, by Valance, 2017-2031

            7.3.1. Monovalent

            7.3.2. Multivalent

        7.4. Market Attractiveness Analysis, by Valance

    8. Global Vaccines Market Analysis and Forecast, by Route of Administration

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Route of Administration, 2017-2031

            8.3.1. Oral

            8.3.2. Injectable

            8.3.3. Others

        8.4. Market Attractiveness Analysis, by Route of Administration

    9. Global Vaccines Market Analysis and Forecast, by Indication

        9.1. Introduction & Definition

        9.2. Key Findings/Developments

        9.3. Market Value Forecast, by Indication, 2017-2031

            9.3.1. Influenza

            9.3.2. Hepatitis

            9.3.3. Polio

            9.3.4. Meningococcal Disease

            9.3.5. Pneumococcal Disease

            9.3.6. DTP

            9.3.7. Rotavirus

            9.3.8. MMR

            9.3.9. Human Papilloma Virus

            9.3.10. Others

        9.4. Market Attractiveness Analysis, by Indication

    10. Global Vaccines Market Analysis and Forecast, by Distribution Channel

        10.1. Introduction & Definition

        10.2. Key Findings/Developments

        10.3. Market Value Forecast, by Distribution Channel, 2017-2031

            10.3.1. Institutional Sales

            10.3.2. Hospital Pharmacies

            10.3.3. Retail Pharmacies

        10.4. Market Attractiveness Analysis, by Distribution Channel

    11. Global Vaccines Market Analysis and Forecast, by Region

        11.1. Key Findings

        11.2. Market Value Forecast, by Region, 2017-2031

            11.2.1. North America

            11.2.2. Europe

            11.2.3. Asia Pacific

            11.2.4. Latin America

            11.2.5. Middle East & Africa

        11.3. Market Attractiveness Analysis, by Region

    12. North America Vaccines Market Analysis and Forecast

        12.1. Introduction

        12.2. Key Findings

        12.3. Market Value Forecast, by Vaccine, 2017-2031

            12.3.1. Inactivated

            12.3.2. Live Attenuated

            12.3.3. Toxoid

            12.3.4. Conjugate

            12.3.5. Others

        12.4. Market Value Forecast, by Valance, 2017-2031

            12.4.1. Monovalent

            12.4.2. Multivalent

        12.5. Market Value Forecast, by Route of Administration, 2017-2031

            12.5.1. Oral

            12.5.2. Injectable

            12.5.3. Others

        12.6. Market Value Forecast, by Indication, 2017-2031

            12.6.1. Influenza

            12.6.2. Hepatitis

            12.6.3. Polio

            12.6.4. Meningococcal Disease

            12.6.5. Pneumococcal Disease

            12.6.6. DTP

            12.6.7. Rotavirus

            12.6.8. MMR

            12.6.9. Human Papilloma Virus

            12.6.10. Others

        12.7. Market Value Forecast, by Distribution Channel, 2017-2031

            12.7.1. Institutional Sales

            12.7.2. Hospital Pharmacies

            12.7.3. Retail Pharmacies

        12.8. Market Value Forecast, by Country/sub-region, 2017-2031

            12.8.1. U.S.

            12.8.2. Canada

        12.9. Market Attractiveness Analysis

            12.9.1. By Vaccine

            12.9.2. By Valance

            12.9.3. By Route of Administration

            12.9.4. By Indication

            12.9.5. By Distribution Channel

            12.9.6. By Country

    13. Europe Vaccines Market Analysis and Forecast

        13.1. Introduction

        13.2. Key Findings

        13.3. Market Value Forecast, by Vaccine, 2017-2031

            13.3.1. Inactivated

            13.3.2. Live Attenuated

            13.3.3. Toxoid

            13.3.4. Conjugate

            13.3.5. Others

        13.4. Market Value Forecast, by Valance, 2017-2031

            13.4.1. Monovalent

            13.4.2. Multivalent

        13.5. Market Value Forecast, by Route of Administration, 2017-2031

            13.5.1. Oral

            13.5.2. Injectable

            13.5.3. Others

        13.6. Market Value Forecast, by Indication, 2017-2031

            13.6.1. Influenza

            13.6.2. Hepatitis

            13.6.3. Polio

            13.6.4. Meningococcal Disease

            13.6.5. Pneumococcal Disease

            13.6.6. DTP

            13.6.7. Rotavirus

            13.6.8. MMR

            13.6.9. Human Papilloma Virus

            13.6.10. Others

        13.7. Market Value Forecast, by Distribution Channel, 2017-2031

            13.7.1. Institutional Sales

            13.7.2. Hospital Pharmacies

            13.7.3. Retail Pharmacies

        13.8. Market Value Forecast, by Country/sub-region, 2017-2031

            13.8.1. Germany

            13.8.2. U.K.

            13.8.3. France

            13.8.4. Italy

            13.8.5. Spain

            13.8.6. Rest of Europe

        13.9. Market Attractiveness Analysis

            13.9.1. By Vaccine

            13.9.2. By Valance

            13.9.3. By Route of Administration

            13.9.4. By Indication

            13.9.5. By Distribution Channel

            13.9.6. By Country/Sub-region

    14. Asia Pacific Vaccines Market Analysis and Forecast

        14.1. Introduction

        14.2. Key Findings

        14.3. Market Value Forecast, by Vaccine, 2017-2031

            14.3.1. Inactivated

            14.3.2. Live Attenuated

            14.3.3. Toxoid

            14.3.4. Conjugate

            14.3.5. Others

        14.4. Market Value Forecast, by Valance, 2017-2031

            14.4.1. Monovalent

            14.4.2. Multivalent

        14.5. Market Value Forecast, by Route of Administration, 2017-2031

            14.5.1. Oral

            14.5.2. Injectable

            14.5.3. Others

        14.6. Market Value Forecast, by Indication, 2017-2031

            14.6.1. Influenza

            14.6.2. Hepatitis

            14.6.3. Polio

            14.6.4. Meningococcal Disease

            14.6.5. Pneumococcal Disease

            14.6.6. DTP

            14.6.7. Rotavirus

            14.6.8. MMR

            14.6.9. Human Papilloma Virus

            14.6.10. Others

        14.7. Market Value Forecast, by Distribution Channel, 2017-2031

            14.7.1. Institutional Sales

            14.7.2. Hospital Pharmacies

            14.7.3. Retail Pharmacies

        14.8. Market Value Forecast, by Country/sub-region, 2017-2031

            14.8.1. China

            14.8.2. India

            14.8.3. Japan

            14.8.4. Australia & New Zealand

            14.8.5. Rest of Asia Pacific

        14.9. Market Attractiveness Analysis

            14.9.1. By Vaccine

            14.9.2. By Valance

            14.9.3. By Route of Administration

            14.9.4. By Indication

            14.9.5. By Distribution Channel

            14.9.6. By Country/Sub-region

    15. Latin America Vaccines Market Analysis and Forecast

        15.1. Introduction

        15.2. Key Findings

        15.3. Market Value Forecast, by Vaccine, 2017-2031

            15.3.1. Inactivated

            15.3.2. Live Attenuated

            15.3.3. Toxoid

            15.3.4. Conjugate

            15.3.5. Others

            15.3.6. Others

        15.4. Market Value Forecast, by Valance, 2017-2031

            15.4.1. Monovalent

            15.4.2. Multivalent

        15.5. Market Value Forecast, by Route of Administration, 2017-2031

            15.5.1. Oral

            15.5.2. Injectable

            15.5.3. Others

        15.6. Market Value Forecast, by Indication, 2017-2031

            15.6.1. Influenza

            15.6.2. Hepatitis

            15.6.3. Polio

            15.6.4. Meningococcal Disease

            15.6.5. Pneumococcal Disease

            15.6.6. DTP

            15.6.7. Rotavirus

            15.6.8. MMR

            15.6.9. Human Papilloma Virus

            15.6.10. Others

        15.7. Market Value Forecast, by Distribution Channel, 2017-2031

            15.7.1. Institutional Sales

            15.7.2. Hospital Pharmacies

            15.7.3. Retail Pharmacies

        15.8. Market Value Forecast, by Country/sub-region, 2017-2031

            15.8.1. Brazil

            15.8.2. Mexico

            15.8.3. Rest of Latin America

        15.9. Market Attractiveness Analysis

            15.9.1. By Vaccine

            15.9.2. By Valance

            15.9.3. By Route of Administration

            15.9.4. By Indication

            15.9.5. By Distribution Channel

            15.9.6. By Country/Sub-region

    16. Middle East & Africa Vaccines Market Analysis and Forecast

        16.1. Introduction

        16.2. Key Findings

        16.3. Market Value Forecast, by Vaccine, 2017-2031

            16.3.1. Inactivated

            16.3.2. Live Attenuated

            16.3.3. Toxoid

            16.3.4. Conjugate

            16.3.5. Others

        16.4. Market Value Forecast, by Valance, 2017-2031

            16.4.1. Monovalent

            16.4.2. Multivalent

        16.5. Market Value Forecast, by Route of Administration, 2017-2031

            16.5.1. Oral

            16.5.2. Injectable

            16.5.3. Others

        16.6. Market Value Forecast, by Indication, 2017-2031

            16.6.1. Influenza

            16.6.2. Hepatitis

            16.6.3. Polio

            16.6.4. Meningococcal Disease

            16.6.5. Pneumococcal Disease

            16.6.6. DTP

            16.6.7. Rotavirus

            16.6.8. MMR

            16.6.9. Human Papilloma Virus

            16.6.10. Others

        16.7. Market Value Forecast, by Distribution Channel, 2017-2031

            16.7.1. Institutional Sales

            16.7.2. Hospital Pharmacies

            16.7.3. Retail Pharmacies

        16.8. Market Value Forecast, by Country/sub-region, 2017-2031

            16.8.1. GCC Countries

            16.8.2. South Africa

            16.8.3. Rest of Middle East & Africa

        16.9. Market Attractiveness Analysis

            16.9.1. By Vaccine

            16.9.2. By Valance

            16.9.3. By Route of Administration

            16.9.4. By Indication

            16.9.5. By Distribution Channel

            16.9.6. By Country/Sub-region

    17. Competition Landscape

        17.1. Market Player Competition Matrix (by tier and size of companies)

        17.2. Market Share Analysis, by Company (2022)

        17.3. Company Profiles

            17.3.1. AstraZeneca

                17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.1.2. Product Portfolio

                17.3.1.3. Financial Overview

                17.3.1.4. SWOT Analysis

                17.3.1.5. Strategic Overview

            17.3.2. GlaxoSmithKline PLC

                17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.2.2. Product Portfolio

                17.3.2.3. Financial Overview

                17.3.2.4. SWOT Analysis

                17.3.2.5. Strategic Overview

            17.3.3. Sanofi Pasteur SA

                17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.3.2. Product Portfolio

                17.3.3.3. Financial Overview

                17.3.3.4. SWOT Analysis

                17.3.3.5. Strategic Overview

            17.3.4. Pfizer Inc.

                17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.4.2. Product Portfolio

                17.3.4.3. Financial Overview

                17.3.4.4. SWOT Analysis

                17.3.4.5. Strategic Overview

            17.3.5. Panacea Biotec

                17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.5.2. Product Portfolio

                17.3.5.3. Financial Overview

                17.3.5.4. SWOT Analysis

                17.3.5.5. Strategic Overview

            17.3.6. Merck & Co., Inc.

                17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.6.2. Product Portfolio

                17.3.6.3. Financial Overview

                17.3.6.4. SWOT Analysis

                17.3.6.5. Strategic Overview

            17.3.7. Janssen Pharmaceutical Company

                17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.7.2. Product Portfolio

                17.3.7.3. Financial Overview

                17.3.7.4. SWOT Analysis

                17.3.7.5. Strategic Overview

            17.3.8. Serus Institute of India Ltd

                17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.8.2. Product Portfolio

                17.3.8.3. Financial Overview

                17.3.8.4. SWOT Analysis

                17.3.8.5. Strategic Overview

            17.3.9. Emergent BioSolutions Inc.

                17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.9.2. Product Portfolio

                17.3.9.3. Financial Overview

                17.3.9.4. SWOT Analysis

                17.3.9.5. Strategic Overview

            17.3.10. CSL

                17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.10.2. Product Portfolio

                17.3.10.3. Financial Overview

                17.3.10.4. SWOT Analysis

                17.3.10.5. Strategic Overview

            17.3.11. Bavarian Nordic

                17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.11.2. Product Portfolio

                17.3.11.3. Financial Overview

                17.3.11.4. SWOT Analysis

                17.3.11.5. Strategic Overview

            17.3.12. IBSS BIOMED S.A.

                17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.12.2. Product Portfolio

                17.3.12.3. Financial Overview

                17.3.12.4. SWOT Analysis

                17.3.12.5. Strategic Overview

            17.3.13. Novavax AB

                17.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.13.2. Product Portfolio

                17.3.13.3. Financial Overview

                17.3.13.4. SWOT Analysis

                17.3.13.5. Strategic Overview

            17.3.14. Mitsubishi Tanabe Pharma Corporation

                17.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.14.2. Product Portfolio

                17.3.14.3. Financial Overview

                17.3.14.4. SWOT Analysis

                17.3.14.5. Strategic Overview

    List of Tables

    Table 01. Global Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031

    Table 02. Global Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031

    Table 03. Global Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 04. Global Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031

    Table 05. Global Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 06. Global Vaccines Market Value (US$ Mn) Forecast, by Region, 2017-2031

    Table 07. North America Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031

    Table 08. North America Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031

    Table 09. North America Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 10. North America Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031

    Table 11. North America Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 12. Europe Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 13. Europe Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031

    Table 14. Europe Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031

    Table 15. Europe Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 16. Europe Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031

    Table 17. Europe Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 18. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 19. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031

    Table 20. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031

    Table 21. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 22. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031

    Table 23. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 24. Latin America Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 25. Latin America Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031

    Table 26. Latin America Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031

    Table 27. Latin America Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 28. Latin America Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031

    Table 29. Latin America Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 30. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 31. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031

    Table 32. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031

    Table 33. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 34. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031

    Table 35. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    List of Figures

    Figure 01. Global Vaccines Market Value (US$ Mn) Forecast, 2017-2031

    Figure 02. Vaccines Market Value Share, by Vaccine, 2022

    Figure 03. Vaccines Market Value Share, by Valance, 2022

    Figure 04. Vaccines Market Value Share, by Route of Administration, 2022

    Figure 05. Vaccines Market Value Share, by Indication, 2022

    Figure 06. Vaccines Market Value Share, by Distribution Channel, 2022

    Figure 07. Global Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031

    Figure 08. Global Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031

    Figure 09. Global Vaccines Market Value Share Analysis, by Valance 2022 and 2031

    Figure 10. Global Vaccines Market Attractiveness Analysis, Valance, 2023-2031

    Figure 11. Global Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031

    Figure 12. Global Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031

    Figure 13. Global Vaccines Market Value Share Analysis, by Indication 2022 and 2031

    Figure 14. Global Vaccines Market Attractiveness Analysis, Indication, 2023-2031

    Figure 15. Global Vaccines Market Value Share Analysis, by Distribution Channel 2022 and 2031

    Figure 16. Global Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031

    Figure 17. Global Vaccines Market Value Share Analysis, by Region, 2022 and 2031

    Figure 18. Global Vaccines Market Attractiveness Analysis, by Region, 2023-2031

    Figure 19. North America Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 20. North America Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031

    Figure 21. North America Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031

    Figure 22. North America Vaccines Market Value Share Analysis, by Valance 2022 and 2031

    Figure 23. North America Vaccines Market Attractiveness Analysis, Valance, 2023-2031

    Figure 24. North America Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031

    Figure 25. North America Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031

    Figure 26. North America Vaccines Market Value Share Analysis, by Indication 2022 and 2031

    Figure 27. North America Vaccines Market Attractiveness Analysis, Indication, 2023-2031

    Figure 28. North America Vaccines Market Value Share Analysis, by Distribution Channel 2022 and 2031

    Figure 29. North America Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031

    Figure 30. Europe Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 31. Europe Vaccines Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 32. Europe Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 33. Europe Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031

    Figure 34. Europe Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031

    Figure 35. Europe Vaccines Market Value Share Analysis, by Valance, 2022 and 2031

    Figure 36. Europe Vaccines Market Attractiveness Analysis, Valance, 2023-2031

    Figure 37. Europe Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031

    Figure 38. Europe Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031

    Figure 39. Europe Vaccines Market Value Share Analysis, by Indication 2022 and 2031

    Figure 40. Europe Vaccines Market Attractiveness Analysis, Indication, 2023-2031

    Figure 41. Europe Vaccines Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 42. Europe Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031

    Figure 43. Asia Pacific Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 44. Asia Pacific Vaccines Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 45. Asia Pacific Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 46. Asia Pacific Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031

    Figure 47. Asia Pacific Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031

    Figure 48. Asia Pacific Vaccines Market Value Share Analysis, by Valance, 2022 and 2031

    Figure 49. Asia Pacific Vaccines Market Attractiveness Analysis, Valance, 2023-2031

    Figure 50. Asia Pacific Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031

    Figure 51. Asia Pacific Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031

    Figure 52. Asia Pacific Vaccines Market Value Share Analysis, by Indication 2022 and 2031

    Figure 53. Asia Pacific Vaccines Market Attractiveness Analysis, Indication, 2023-2031

    Figure 54. Asia Pacific Vaccines Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 55. Asia Pacific Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031

    Figure 56. Latin America Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 57. Latin America Vaccines Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 58. Latin America Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 59. Latin America Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031

    Figure 60. Latin America Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031

    Figure 61. Latin America Vaccines Market Value Share Analysis, by Valance, 2022 and 2031

    Figure 62. Latin America Vaccines Market Attractiveness Analysis, Valance, 2023-2031

    Figure 63. Latin America Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031

    Figure 64. Latin America Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031

    Figure 65. Latin America Vaccines Market Value Share Analysis, by Indication 2022 and 2031

    Figure 66. Latin America Vaccines Market Attractiveness Analysis, Indication, 2023-2031

    Figure 67. Latin America Vaccines Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 68. Latin America Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031

    Figure 69. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 70. Middle East & Africa Vaccines Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 71. Middle East & Africa Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 72. Middle East & Africa Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031

    Figure 73. Middle East & Africa Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031

    Figure 74. Middle East & Africa Vaccines Market Value Share Analysis, by Valance, 2022 and 2031

    Figure 75. Middle East & Africa Vaccines Market Attractiveness Analysis, Valance, 2023-2031

    Figure 76. Middle East & Africa Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031

    Figure 77. Middle East & Africa Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031

    Figure 78. Middle East & Africa Vaccines Market Value Share Analysis, by Indication 2022 and 2031

    Figure 79. Middle East & Africa Vaccines Market Attractiveness Analysis, Indication, 2023-2031

    Figure 80. Middle East & Africa Vaccines Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 81. Middle East & Africa Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031

Copyright © Transparency Market Research, Inc. All Rights reserved